1 nfarction, which may have contributed to the
mortality decline.
2 condary diagnosis of pneumonia increased and
mortality declined.
3 Non-White
mortality declined 10 PP (P < 0.01).
4 5% in 1991 through 1995, P < .05), operative
mortality declined (
13% in 1966 through 1985; 0% in 1991
5 Age-adjusted heart disease
mortality declined 27% in nondiabetic women but increase
6 (40.1% vs. 71.9%; P < 0.0001), and hospital
mortality declined (
38.1% vs. 14.7%; P < 0.0001).
7 CLD
mortality declined 5% overall from 1990 through 1994 (12
8 Cardiovascular disease
mortality declined 59% between the female cohorts and 53
9 After multivariable adjustment, odds of
mortality declined 61% by the year 2009.
10 Waitlist
mortality declined 8 percentage points (PP) across eras
11 Between the 2000s and 2010s, the
mortality decline accelerated in China, central and east
12 regional studies and found that in-hospital
mortality declined across all age groups during the peri
13 In multivariable analysis, all-cause
mortality declined (
adjusted mortality rate ratio [aMRR]
14 past reproductive age, and why does juvenile
mortality decline after birth, both contrary to the clas
15 ic mortality patterns were different: non-AN
mortality declined after age 25-29 and stayed relatively
16 Mortality declines aggregated across all age groups mask
17 nning of HIV treatment scale-up in 2004, HIV
mortality declined among both men and women.
18 e found that from 2000 through 2011, overall
mortality declined among extremely premature infants.
19 en and men, the HR of cardiovascular disease
mortality declined among those with and without diabetes
20 Non-cardiovascular disease
mortality declined among women without diabetes mellitus
21 l 48.9% between 1990 and 2018, mainly due to
mortality declines among Black Americans.
22 As inpatient sepsis
mortality declines,
an increasing number of initial seps
23 NADCs will likely grow in importance as AIDS
mortality declines and PWHIV age.
24 As child
mortality declines and the human population ages, data f
25 a constraint on any theory of society-driven
mortality decline,
and provides a basis for stochastic m
26 he poor understanding of the factors driving
mortality decline,
and the difficulty of forecasting mor
27 > or =11 and < or =12, and >12 g/dl, risk of
mortality declined as Hb level increased.
28 middle through old age despite a consistent
mortality decline at infant through old age for communic
29 ing the first decade of the 21st century, HD
mortality declined at a much greater rate than cancer mo
30 After outlier designation, in-hospital
mortality declined at outlier institutions to a greater
31 We estimated that 61.2% of global maternal
mortality decline between 2000 and 2023 was attributable
32 and increased contraceptive use on maternal
mortality decline between 2000 and 2023.
33 neither all-cause nor cardiovascular disease
mortality declined between 1971 to 1986 and 1988 to 2000
34 CVD
mortality declined between 2000 and 2011 (AAPC, -3.1%; 9
35 All-cause
mortality declined between 2000 and 2012 (AAPC, -2.6%; 9
36 In 2016-2017, the national HCV-associated
mortality declined but rates remained high in the Wester
37 In 2016-2017, national HCV-associated
mortality declined but remained high in western and sout
38 Direct obstetric
mortality declined by 3% per year (rate ratio 0.97 per y
39 .1 percent per year, whereas out-of-hospital
mortality declined by 3.6 percent per year.
40 , other, or multiple races/ethnicities]), CV
mortality declined by 45.5% overall and by 38.4% in high
41 this total decrease of 34% (27-41), under-5
mortality declined by 59% (56-61) in this period.
42 Maternal
mortality declined by 8.9% per year between 1997 and 201
43 From 1966 to 1982, the
mortality declined by an average of 13.0 percent annuall
44 2017, with incidence declining by 27.9% and
mortality declining by 42.5%.
45 The biggest contributions to the CHD
mortality decline came from secular decreases in blood p
46 , and 31.0%; P=0.003 for trend, but adjusted
mortality declined (
compared with 1992-1993, relative ri
47 Adjusted rates of hospitalization and
mortality declined consistently in the subgroup with a p
48 For ages 50-69 years,
mortality decline decelerated in all regions except sub-
49 ce 1969 is due to the faster pace of old-age
mortality decline during recent decades.
50 ter <or=10 microm in aerodynamic diameter on
mortality declined during 1987-2000 and that this declin
51 Mortality declined during that time but remained >50% du
52 Infectious disease
mortality declined during the first 8 decades of the 20t
53 Operative
mortality declined during the study period for both inta
54 unted for approximately 52% (40%-70%) of the
mortality decline,
equitably distributed across all soci
55 han NCDs, but overall bolstered by the adult
mortality decline,
especially in women.
56 In-hospital
mortality declined faster than out-of-hospital mortality
57 From 1970 to 1994, varicella
mortality declined,
followed by an increase.
58 Operative
mortality declined for all eight procedures, ranging fro
59 After 1994, calendar period
mortality declined for both.
60 The female-to-male rate ratio for HIV
mortality declined from 0.93 (95% CI 0.82-1.07) in 2003
61 For women, HIV
mortality declined from 1.60 deaths per 100 person-years
62 For men, HIV-related
mortality declined from 1.71 per 100 person-years (95% C
63 stay fell from 8.3 to 4.3 days, and hospital
mortality declined from 11.2% to 9.4% (both p = 0.0001).
64 Between 1980 to 1989 and 2000 to 2009, MI
mortality declined from 12.5% to 3.2% within 30 days, 5.
65 0 and 2002 (P = .005), and treatment-related
mortality declined from 19% to 12% (P = .025).
66 Premature
mortality declined from 2000-03 to 2012-15 among black a
67 Mortality declined from 21.7% in 2004 to 9.7% in 2010 am
68 ncreased 9.3% from 0.44 to 0.48 per 1000 and
mortality declined from 25.1% to 19.2% (ARR, 6.0%; 95% C
69 Mortality declined from 44.7 to 27.1 (P<0.0001) for thos
70 Overall
mortality declined from 45% in 2008 to 27% in 2017, wher
71 Overall, cancer-attributable
mortality declined from 484.0 per 100 000 person-years d
72 Mortality declined from 5.3 percent in 1996 to 2.1 perce
73 In-hospital
mortality declined from 62.2% in 1997 to 36.3% in 2017 (
74 nomous region during the same period, infant
mortality declined from 64 to 59 per 1000 and under-5 mo
75 Kaplan-Meier estimates of 6-month
mortality declined from 7.0% [95% confidence interval 6.
76 Risk-adjusted 30-day post-discharge
mortality declined from 7.1% in 2006 to 6.6% in 2017.
77 Under-5
mortality declined from 95.4 (95% UI 90.1-101.3) deaths
78 Without the aid of CVD
mortality declines,
future US life expectancy gains must
79 health interventions in seeking significant
mortality decline in the middle age group of 50-69 years
80 The
mortality decline in the USA was greatest and most susta
81 8.7 to 29.3) from 1990 to 2015, the rates of
mortality decline in this period substantially varied ac
82 Cardiovascular
mortality declined in all subgroups during the 35-year s
83 ed with increased mortality in group II, but
mortality declined in group III despite the continued in
84 Mortality declined in patients with AIDS (39% in 1999 to
85 Suicide
mortality declined in the general population after 2005[
86 Female lung cancer
mortality declined in the young (-35.8%, ASR: 0.8/100 00
87 Slowing
mortality declines in some regions require enhanced effo
88 ociated with the risk of COPD exacerbations,
mortality, decline in FEV1, and response to both inhaled
89 creased in Romania and Japan; therefore, the
mortality decline is not universal.
90 omania, Austria, and Denmark; therefore, the
mortality decline is not universal.
91 Risk of
mortality declined log-linearly with gestational age.
92 Over the past 25 years, CVD
mortality declined markedly in the community, but there
93 ck 48-hour, 3-14-day and greater than 14-day
mortality declined markedly over two decades; in contras
94 Between 2004 and 2008, all-cause adult
mortality declined more in PEPFAR focus countries relati
95 One-year
mortality declined more in programs with high (from 25.6
96 urred in the 1-59 months age group; neonatal
mortality declined more slowly (from 50 to 23 deaths per
97 The largest absolute
mortality decline occurred in the 0- to 30-day period wi
98 The most rapid
mortality decline occurred in the 1-59 months age group;
99 The largest
mortality declines occurred between the 1950 and 1960 fe
100 Mortality declines of the early 1990s were not sustained
101 t when a population has experienced a smooth
mortality decline or only short periods of excess mortal
102 ulations that have experienced either smooth
mortality declines or only short periods of excess morta
103 usted 10-year hazard ratio (HR) of all-cause
mortality declined over the 3 eras, as did years of life
104 The adjusted hazard of 5-year all-cause
mortality declined over the four eras = 0.77; 95% CI, 0.
105 Ovarian cancer
mortality declined over the past decade in all considere
106 Wait-list
mortality declined over the past decade, including among
107 15 developed countries shows that, as infant
mortality declined over two centuries, the excess male m
108 Cancer
mortality declined overall in the United States between
109 e age group and a benign contribution of old
mortality decline owing to the low threshold age.
110 While acute myocardial infarction
mortality declines,
patients continue to face reinfarcti
111 Primary postpartum haemorrhage morbidity and
mortality declined rapidly nationwide.
112 yses have shown that the value of achievable
mortality declines remains high and indeed is often a su
113 Mortality declined significantly after universal ART rec
114 from 2019 to 2024, risk-adjusted in-hospital
mortality declined significantly following the COVID-19
115 past 2 decades, age-adjusted cardiovascular
mortality declined significantly for Black and White adu
116 However, observed in-hospital
mortality declined significantly for women from 2001 to
117 GBS-attributable
mortality declined significantly from 0.044 (95% CI .029
118 creased slightly over time, observed 6-month
mortality declined significantly in all age strata (1994
119 emiology, the incidence of MI and associated
mortality declined significantly in all US Census Divisi
120 Although
mortality declined significantly in recent years, novel
121 Heart disease
mortality declined significantly in whites (237 to 216 p
122 Risk-adjusted in-hospital
mortality declined slightly in the overall cohort from 9
123 Between 1988 and 2002, in-hospital
mortality declined steadily in patients with ARF (40.4 t
124 ate (U5MR), offering an experiential view of
mortality decline that annualized measures conceal.
125 While HAV-related
mortality declined,
the mean age at death among decedent
126 itical care advances and intensive care unit
mortality declines,
the number of survivors of critical
127 For blacks, calendar period
mortality declined until the late 1970s, and then sharpl
128 in all jurisdictions, with contributions to
mortality declines varying by country in those aged 55-7
129 In the US population, no acceleration of
mortality decline was observed in either ACVD or CAD mor
130 Adults >/=65 years of age showed consistent
mortality declines,
which became even steeper after 2000
131 ssociation of a breast cancer diagnosis with
mortality declined with age among women with advanced di
132 Associations between income inequality and
mortality declined with age at death, and then reversed
133 AIDS-related
mortality declined with increasing CD4:CD8 ratio and dec
134 Risk-adjusted
mortality declined with increasing discharge delay and w
135 ith severe sepsis, although its influence on
mortality declined with time.
136 Rates of all-cause
mortality declined with time: the average adjusted morta
137 g postreproductive survival and why juvenile
mortality declines with age.
138 All-cause
mortality declined,
with large declines for cardiovascul
139 was used to determine whether divergence of
mortality declines would be expected under an assumption